Clinical Trials
11 trialsNCT07551362 2026-04-24
DUET-GEJ
Beijing Biotech
Phase 1/2 Recruiting
NCT07523529 2026-04-13
SELECT-2CAR
Beijing Biotech
Phase 1/2 Recruiting
NCT04426669 2026-02-23
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
Intima Bioscience, Inc.
Phase 1/2 Completed
NCT05678205 2025-07-30
A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
Artiva Biotherapeutics, Inc.
Phase 1/2 Withdrawn
NCT02876510 2025-02-04
ACTolog
Immatics US, Inc.
Phase 1 Completed
NCT06341647 2025-01-24
Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201
GC Cell Corporation
Phase 1 Withdrawn
NCT05207722 2024-12-12
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Celularity Incorporated
Phase 1/2 Terminated
NCT04319757 2024-12-05
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Acepodia Biotech, Inc.
Phase 1 Completed
NCT04282044 2024-02-08
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
BioEclipse Therapeutics
Phase 1 Recruiting
NCT05069935 2023-09-21
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
NCT03841110 2023-05-01
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Completed